Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Summary

This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pembrolizumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread.

Timeline

Start

2022-05-03

Primary completion

2023-12-31

Completion

2023-12-31

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Accrual”

Drugs

Indications